These are publications from work undertaken by Frontier Science (Scotland).

M Procter; 

Simulation Study to Estimate Bias of Treatment Effect in Pain Scores in Diabetic Neuropathy

Pain Medicine,  24 August 2019, online first: doi:10.1093/pm/pnz192

C Kersten;  M G Cameron; A G Bailey; M T Fallon; B J Laird; V Paterson; R Mitchell; S M Fleetwood-Walker; F Daly; S Mjåland;  20 May 2019

Relief of Neuropathic Pain Through Epidermal Growth Factor Receptor Inhibition: A Randomized Proof-of-Concept Trial

Pain Medicine,  20 May 2019, online first: doi:10.1093/pm/pnz101

J F R Robertson;  Z Jiang; A Di Leo; S Ohno; K I Pritchard; M Ellis; I Bradbury; C Campbell;  May 2019

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

Breast Cancer,  11 May 2019, online first doi:10.1007/s12282-019-00973-4

W P Kirschbrown;  M Kågedal; B Wang; L Lindbom; A Knott; R Mack; S Monemi; I Nijem; S Girish; C Freeman; D Fumagalli; R McConnell; G Jerusalem; C Twelves; J Baselga; G von Minckwitz; J Bines; A Garg;  June 2019

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

Cancer Chemotherapy and Pharmacology,  Volume 83, Issue No 6, pp. 1147-1158 doi:10.1007/s00280-019-03826-1

Rajiv Mallick;  Stephen Jolles; Hirokazu Kanegane; Dominique Agbor-Tarh; Mikhail Rojavin;  21 November 2018

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: A Pooled Analysis of Six Hizentra® Studies

Journal of Clinical Immunology,  1 - 12, doi:10.1007/s10875-018-0562-3

M Lambertini;  S Martel; C Campbell; S Guillaume; F Hilbers; U Schuehly; L Korde; H A Azim; S Di Cosimo; R C Tenglin; J Huober; J Baselga; A Moreno-Aspitia; M Piccart-Gebhart; RD Gelber; E. de Azambuja; M Ignatiadis;  Published online first 01 June 2018

Pregnancies during and following trastuzumab and/or lapatinib in patients with HER2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials in Cancer

Journal of Clinical Oncology,  Volume 36, No. 15, doi:10.1200/JCO.2018.36.15_suppl.10065

M Procter;  C Robertson;  Published online first 13 August 2018

Performance of Standard Imputation Methods for Missing Quality of Life Data as Covariate in Survival Analysis Based on Simulations from the International Breast Cancer Study Group Trials VI and VII

Communication in Statistics - Simulation and Computation,  Pages: 1-15, doi: 10.1080/03610918.2018.1473587

M Procter;  C Robertson;  Published online first 15 December 2017

Imputing Missing Quality of Life Data as Covariate in Survival Analysis of the International Breast Cancer Study Group Trials VI and VII

Communications in Statistics - Simulation and Computation,  Pages 1 - 11, doi:10.1080/03610918.2017.1390123

A Sonnenblick;  D Agbor-Tarh; I Bradbury; S Di Cosimo; J A Zujewski; H A Azim Jr; J Judith; M Andersson; T Cufer; S Simon; P Salman; M Toi; L Harris; J Gralow; A Moreno-Aspitia; M. Piccart; E. de Azambuja; K Macoon;  May, 2017

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial

Journal of Clinical Oncology,  Volume 35, Issue 13, 1421-1429, doi:10.1200/JCO.2016.69.7722

G von Minckwitz;  M Procter; E. de Azambuja; D Zardavas; M Benyunes; G Viale; T M Suter; A Arahmani; N Rouchet; E Clark; A Knott; I Lang; C Levy; D Yardley; J Bines; RD Gelber; M. Piccart; J Baselga;  July 13, 2017

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

The New England Journal of Medicine,  Volume 377, Issue 2, pp. 122-131, doi: 10.1056/NEJMoa1703643